Literature DB >> 16702955

Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis.

H Chen1, M Li, R A Campbell, K Burkhardt, D Zhu, S G Li, H J Lee, C Wang, Z Zeng, M S Gordon, B Bonavida, J R Berenson.   

Abstract

The tumor necrosis factor receptor (TNFR)-associated factor (TRAF) family of six adaptor proteins (TRAF1-6) links the TNFR superfamily to the nuclear factor kappa B (NF-kappaB) and activator protein-1 (AP-1) transcriptional activators. Unlike other TRAFs, TRAF6 is also involved in Toll-like/interleukin (IL)-1 receptor (TIR) signal transduction. Thus, inhibition of TRAF6 function could interrupt both CD40 (TNFR family) and IL-1 growth signals, pathways critical to myeloma proliferation. To block TRAF6-mediated IL-1 signaling, we constructed small interfering RNA (siRNA) against TRAF6. We found that siRNA targeting the TRAF6 C-terminal (siTRAF6C) receptor interaction domain specifically reduced only TRAF6 protein expression, without affecting TRAF2 or 5 levels, and substantially interfered with IL-1-induced NF-kappaB and c-Jun/AP-1 activation. Inhibition by siTRAF6C was concentration-dependent. SiTRAF6C also significantly reduced myeloma proliferation and enhanced apoptosis in a similar dose-dependent fashion in vitro. More importantly, marked siTRAF6C growth inhibition was detected in vivo when these cells were implanted into the bone marrow of irradiated normal mice. In contrast, introduction of siRNA derived from the TRAF6 Zn-finger domain or an irrelevant siRNA construct failed to alter cell growth or cell death. These studies suggest that TRAF6 may be a new molecular target to block cell signal transduction important for the survival and proliferation of multiple myeloma cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16702955     DOI: 10.1038/sj.onc.1209653

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  13 in total

Review 1.  TRAF6 activation in multiple myeloma: a potential therapeutic target.

Authors:  Hong Liu; Samantha Tamashiro; Stavroula Baritaki; Manuel Penichet; Youhua Yu; Haiming Chen; James Berenson; Benjamin Bonavida
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-03-21

2.  The Ran-binding protein RanBPM can depress the NF-κB pathway by interacting with TRAF6.

Authors:  Lan Wang; Chengbo Fu; Yingbin Cui; Yunfei Xie; Yuhe Yuan; Xin Wang; Hong Chen; Bing-Ren Huang
Journal:  Mol Cell Biochem       Date:  2011-07-30       Impact factor: 3.396

3.  MiR-146a affects the alteration in myeloid differentiation induced by hydroquinone in human CD34+ hematopoietic progenitor cells and HL-60 cells.

Authors:  Weixin Yuan; Qing Sun; Yanping Jiang; Xinjie Zhang; Liping Chen; Chunjiao Xie; Fei Qin; Yuncong Chen; Hongxin Lv; Wen Chen; Yongmei Xiao
Journal:  Toxicol Res (Camb)       Date:  2016-02-16       Impact factor: 3.524

4.  TRAF6 expression is associated with poorer prognosis and high recurrence in urothelial bladder cancer.

Authors:  Hanli Wu; Aixia Hao; Honghong Cui; Wenbin Wu; Huanrong Yang; Baohong Hu; Peng Li
Journal:  Oncol Lett       Date:  2017-06-20       Impact factor: 2.967

5.  Characterization of apoptosis and proliferation in esophageal carcinoma EC109 cells following siRNA-induced down-regulation of TRAF6.

Authors:  Tianzhong Ma; Ning Wang; Zhongjing Su; Ling Chen; Ningxia Zhu; Changhui Ma; Xiancai Chen; Haibin Chen
Journal:  Mol Cell Biochem       Date:  2011-02-11       Impact factor: 3.396

6.  TRAF6 is required for BLyS-mediated NF-κB signaling in multiple myeloma cells.

Authors:  Xinfeng Wang; Jingjing Wang; Hong Liu; Ruirong Xu; Runsheng Ding; Shenhua Jiang; Xudong Wang; Hongming Huang
Journal:  Med Oncol       Date:  2015-09-03       Impact factor: 3.064

Review 7.  NF-kappaB and cancer-identifying targets and mechanisms.

Authors:  Willscott E Naugler; Michael Karin
Journal:  Curr Opin Genet Dev       Date:  2008-04-24       Impact factor: 5.578

8.  Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype.

Authors:  Daniel T Starczynowski; Florian Kuchenbauer; Bob Argiropoulos; Sandy Sung; Ryan Morin; Andrew Muranyi; Martin Hirst; Donna Hogge; Marco Marra; Richard A Wells; Rena Buckstein; Wan Lam; R Keith Humphries; Aly Karsan
Journal:  Nat Med       Date:  2009-11-08       Impact factor: 53.440

9.  Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.

Authors:  Teru Hideshima; Hiroshi Ikeda; Dharminder Chauhan; Yutaka Okawa; Noopur Raje; Klaus Podar; Constantine Mitsiades; Nikhil C Munshi; Paul G Richardson; Ruben D Carrasco; Kenneth C Anderson
Journal:  Blood       Date:  2009-05-12       Impact factor: 22.113

Review 10.  Discovery and development of small molecule SHIP phosphatase modulators.

Authors:  William G Kerr; John D Chisholm; Dennis R Viernes; Lydia B Choi
Journal:  Med Res Rev       Date:  2013-12-02       Impact factor: 12.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.